Organization

Regeneron Pharmaceuticals

0 members

What's driving coverage of Regeneron Pharmaceuticals right now?

Corporate ratings

High risk

Regeneron scored High Risk because it has adopted identity-based hiring and philanthropic practices that prioritize demographic outcomes over merit, and because its governance and advocacy activities lean heavily into partisan and divisive social causes. These practices, spanning cancellations, discriminatory philanthropy, employment policy, and political engagement, suggest the company has allowed activism to shape its corporate decision-making rather than focusing on core business objectives.

CancellationsMedium risk
Discriminatory PhilanthropyHigh risk
Employment ProtectionHigh risk
Advocacy BiasHigh risk
FundingHigh risk
Political ActionsHigh risk

Assessment by 1792 Exchange. Summary generated by IJR from their published rating.

coverage spread: L21/C21/R57

Comments

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Health
FDA Approves Regeneron Pasatru for FOP
Regeneron's garetosmab, marketed as Pasatru, received FDA approval to treat adults with fibrodysplasia ossificans progressiva, becoming the second FDA-cleared therapy for FOP and the first to reduce clinician-assessed flare-ups. Driven by OPTIMA/phase 3 data showing about 90% reduction in new bone lesions over 56 weeks and substantial decreases in flare-ups, Pasatru competes with Ipsen's Sohonos and awaits EMA/Japan submissions, with price not disclosed.
6 sources

Regeneron Pharmaceuticals

0 members

What's driving coverage of Regeneron Pharmaceuticals right now?

Corporate ratings

High risk

CancellationsMedium risk
Discriminatory PhilanthropyHigh risk
Employment ProtectionHigh risk
Advocacy BiasHigh risk
FundingHigh risk
Political ActionsHigh risk

Assessment by 1792 Exchange. Summary generated by IJR from their published rating.

coverage spread: L21/C21/R57

Comments

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Health
FDA Approves Regeneron Pasatru for FOP
Regeneron's garetosmab, marketed as Pasatru, received FDA approval to treat adults with fibrodysplasia ossificans progressiva, becoming the second FDA-cleared therapy for FOP and the first to reduce clinician-assessed flare-ups. Driven by OPTIMA/phase 3 data showing about 90% reduction in new bone lesions over 56 weeks and substantial decreases in flare-ups, Pasatru competes with Ipsen's Sohonos and awaits EMA/Japan submissions, with price not disclosed.
6 sources

Regeneron Pharmaceuticals across IJR

Ask Genius by OpenServe about Regeneron Pharmaceuticals Create in Studio Build a game Watch videos

Overview

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Company history The company was founded by CEO Leonard Schleifer and scientist George Yancopoulos in 1988. Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is normally involved in inflammation. On March 26, 2012, Bloomberg announced that Sanofi and Regeneron were in development of a new drug that would help reduce cholesterol up to 72% more than its competitors. The new drug would target the PCSK9 gene.

From Wikipedia (CC BY-SA 4.0).

Regeneron Pharmaceuticals

Corporate ratings

Comments

FDA Approves Regeneron Pasatru for FOP

Regeneron Pharmaceuticals

Corporate ratings

Comments

FDA Approves Regeneron Pasatru for FOP

Regeneron Pharmaceuticals across IJR

Overview

Overview

Regeneron Pharmaceuticals across IJR